Bifidobacterium and lactobacillus counts and IL-4 levels weresignificantly higher in the observation group than in the control group.Conclusion: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level ofinflammatory cytokines; therefore, it is worthy of further clinical validation.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Background/Aims: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probioticson the microflora composition and prognosis in patients with inflammatory bowel disease (IBD).Materials and Methods: A total of 40 patients with IBD (19 control group and 21 observation group) were randomized.
📊
Temel Bulgular & Veri:The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed.Results: After treatment, the number of enterobacteria, enterococci, saccharomyces, and bacteroides; the levels of fecal lactoferrin,1-antitrypsin, β2-microglobulin, high-sensitivity C-reactive protein, and interleukin (IL)-6; activity scores; and recurrence rate in the observation group were significantly lower than those in the control group.
💡
Sonuç & Katkı:Bifidobacterium and lactobacillus counts and IL-4 levels weresignificantly higher in the observation group than in the control group.Conclusion: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level ofinflammatory cytokines; therefore, it is worthy of further clinical validation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Background/Aims: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probioticson the microflora composition and prognosis in patients with inflammatory bowel disease (IBD).Materials and Methods: A total of 40 patients with IBD (19 control group and 21 observation group) were randomized. Patients in thecontrol group were given pentasa, and patients in the observation group were given probiotics along with pentasa. The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed.Results: After treatment, the number of enterobacteria, enterococci, saccharomyces, and bacteroides; the levels of fecal lactoferrin,1-antitrypsin, β2-microglobulin, high-sensitivity C-reactive protein, and interleukin (IL)-6; activity scores; and recurrence rate in the observation group were significantly lower than those in the control group. Bifidobacterium and lactobacillus counts and IL-4 levels weresignificantly higher in the observation group than in the control group.Conclusion: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level ofinflammatory cytokines; therefore, it is worthy of further clinical validation.
🔖
Bu Makaleye Atıf Yap
FAN, H., DU, J., LIU, X., ZHENG, W. W., ZHUANG, Z. H., WANG, C. D., GAO, R. (2019). Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 8, 680–685. https://ajindex.com/articles/408829
Rhodes J, Thomas G, Evans BK. Inflammatory Bowel Disease Management. Drugs 1997; 53: 189-94. [CrossRef] 2. Zurek M, Kern I, Manuwald U, et al. Epidemiology and care structures for children and adolescents and young adults up to the 26th year of life with inflammatory bowel diseases (IBD) in Leipzig/Saxony/Germany. J Public Health 2018: 1-6. [CrossRef] 3. Chadwick VS, Chen W. The intestinal microflora and inflammatory bowel disease. Medical Importance of the Normal Microflora. Kluwer Academic Publishers,
Dordrecht, The Netherlands. 1999; 177-221. [CrossRef] 4. Bamias G, Pizarro T, Cominelli F. New Paradigms in the Pathogenesis of IBD. Inflamm Bowel Dis 2011: 41-57. [CrossRef] 5. Dong X, Ye X, Chen X, et al. Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease. Dig Dis Sci 2014; 59: 769-77. [CrossRef] 6. Hong HJ, Kim J, Yong JS, Kim D, Roh KM, Kang I. pH-Sensitive mesalazine carrier for colon-targeted drug delivery: A two-fold composition of mesalazine with a clay and alginate. Macromolecular Res 2017; 25: 1145-52. [CrossRef] 7. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol 2011; 2: 94. [CrossRef] 8. Chandler M, Wollins E, Toles A, Borum M, Doman DB. The emerging therapeutic role of probiotics in inflammatory bowel disease. Gastroenterol Hepatol 2008; 4: 634-40. 9. Khanna PV, Shih DQ, Haritunians T, McGovern DP, Targan S. Use of animal models in elucidating disease pathogenesis in IBD. Semin Immunopathol 2014; 36: 541-51. [CrossRef] 10. Kamp KJ, Brittain K. Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review. Patient 2018: 1-14. [CrossRef] 11. Munkholm P, Pedersen N. Evaluation of Quality of Life in Inflammatory Bowel Disease. Crohn’s Disease and Ulcerative Colitis 2012: 333-40. [CrossRef] 12. Andre MF, Aumaitre O, Piette JC, et al. Analysis of the NOD2/ CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease. Dig Dis Sci 2008; 53: 490-9. [CrossRef] 13. Liu ZJ. New progress in the pathogenesis of inflammatory bowel disease. J Intern Med Concepts Prac 2013; 8: 5-8. 14. Ihara S, Hirata Y, Koike K. TGF-beta in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol 2017; 52: 777-87. [CrossRef] 15. Okamoto R, Watanabe M. Role of epithelial cells in the